等待开盘 11-18 09:30:00 美东时间
0.000
0.00%
Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(0.03) per share. This is a 93.33 percent increase over losses of $(0.45) per share from the same period last year.
11-12 21:04
Theriva Biologics sold its portfolio of antibiotic-degrading enzymes, including SYN-004 (ribaxamase), SYN-007, and SYN-006, to Biossil Labs for $350,000 upfront, with potential milestone payments of up to $91 million and low single-digit royalties. Biossil will handle future development and commercialization. The deal aims to advance clinical trials targeting prevention of infections like C. difficile and aGVHD in transplant patients.
11-02 13:00
Theriva Biologics announced the publication of VIRAGE Phase 2b trial results in *Nature Medicine*, showing VCN-01 combined with chemotherapy improved survival and response in metastatic pancreatic cancer patients. The study suggests VCN-01 may act through an immune-mediated mechanism. Theriva is evaluating more frequent dosing in the VIRAGE2 Phase 2a trial to potentially enhance clinical outcomes. VCN-01 has received orphan drug designations and ...
09-30 12:00
Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. This is a 96.37 percent increase over losses of $(1.93) per share from the same period last year.
08-11 20:06
Theriva Biologics ( ($TOVX) ) just unveiled an update. On July 7, 2026, Theriva...
07-07 20:28
Theriva Biologics has received authorization from the Spanish Agency of Medicines and Medical Devices (AEMPS) to initiate the VIRAGE2 clinical trial, which aims to evaluate the feasibility of administering at least three doses of VCN-01 (zabilugene almadenorepvec) with 2 months between doses in combination with standard-of-care chemotherapy for patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC). This trial builds on ...
07-07 12:00
– Prolonged overall survival (OS) was observed in heavily pre-treated refractory Head & Neck Squamous Cell Carcinoma (HNSCC) patients administered IV VCN-01 prior to the immune checkpoint inhibitor durvalumab – – Pharmacokinetic, tissue biopsy, radiomic and transcriptomic results all support the pro...
06-11 20:43
Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(0.05) per share which met the analyst consensus estimate. This is a 96.77 percent increase over losses of $(1.55) per share from the same period last year.
05-06 04:47
Theriva Biologics Inc. shares are trading higher Monday after announcing upcoming poster on VIRAGE phase 2b VCN-01 pancreatic cancer trial.
04-20 22:05
- Tumor reponse, biomarker, and subgroup analyses from the VIRAGE Phase 2b clinical trial support a VCN-01 immune-mediated mode of action and demonstrate improved outcomes in VCN-01 treated patients across multiple
04-18 04:08